NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference

Company’s lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023 CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe…

Click here to view original post